Baseline systemic immune profiles predict prognosis and differential benefit from ipilimumab intensification in relapsed mesothelioma (Bio-IFCT-1501 MAPS2 trial) (SITC 2026) - Oct 2, 2026 - Abstract #36; Pres time: Nov 7, 2026; 10:00 AM - 08:10 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Mesothelioma • Oncology • Solid Tumor
|
|
Matthieu Roulleaux Dugage; Guillaume Tosato; Aurélien Marabelle; Arnaud Scherpereel; Jean Jouniaux; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Alexandra Langlais; Elodie Amour; Yuna Blum; Didier Jean; David Planchard; Gerard Zalcman; Nathalie Chaput
|